November 13, 2024
2 min watch
Save
VIDEO: Oral Stargardt’s disease treatment focuses on reducing vitamin A dimerization
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Michel Dahan, CEO of Alkeus Pharmaceuticals discusses ALK-001, the company’s oral therapy for the treatment of Stargardt’s disease and age-related macular degeneration.
ALK-001 (gildeuretinol) is “a new chemical entity designed to lower dimerization in the retina and do so without modulating the visual cycle,” he said.
Dahan also discussed a trial investigating the oral treatment for geographic atrophy.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Dahan reports being the CEO of Alkeus Pharmaceuticals.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.